Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Non-Small Cell Lunch Cancer × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 72 Carcinoma, Non-Small-Cell Lung 67 Ovarian Neoplasms 61 Neoplasms 61 Fallopian Tube Neoplasms 28 Carcinoma, Ovarian Epithelial 28 Neoplasm Metastasis 26 Unspecified Adult Solid Tumor, Protocol Specific 23 Lung Neoplasms 22 Stomach Neoplasms 16 Esophageal Neoplasms 16 Triple Negative Breast Neoplasms 15 Colorectal Neoplasms 14 Endometrial Neoplasms 13 Head and Neck Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 11 Solid Tumors 11 Pancreatic Neoplasms 9 Prostatic Neoplasms 8 Melanoma 8 Lymphoma, Large B-Cell, Diffuse 8 Lymphoma 8 Carcinoma 8 Brenner Tumor 8 Uterine Cervical Neoplasms 7 Urinary Bladder Neoplasms 7 Small Cell Lung Carcinoma 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Lymphoma, Non-Hodgkin 7 Lymphoma, Mantle-Cell 7

Interventions

Paclitaxel 1 NVP-BKM120 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01820325 2018-10-11

BASALT-2

Novartis

Phase 1 Terminated

Non-Small Cell Lunch Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡